H4943 requires a broad range of Massachusetts health coverage arrangements to cover the appropriate weight-based dosage of epinephrine injectors, including auto-injectors and FDA-approved pre-filled syringes that deliver equivalent doses. The bill applies to coverage offered through the Group Insurance Commission for active and retired state employees, MassHealth and its managed care contractors, and multiple categories of private insurance products, including commercial health insurance, hospital service plans, medical service agreements, and health maintenance contracts.
The bill also bars insurers and other covered entities from imposing higher deductibles, coinsurance, copayments, or out-of-pocket limits on epinephrine injectors than those applied to comparable covered drugs or benefits. By defining “epinephrine injector” to include both auto-injectors and certain pre-filled syringes, the bill appears intended to ensure access to weight-appropriate emergency allergy treatment for children and adults who may need different dosage forms.
Impact
If enacted, H4943 would amend Chapters 32A, 118E, 175, 176A, 176B, and 176G of the General Laws to create a uniform coverage mandate for epinephrine injectors across public employee, Medicaid, and private insurance markets in Massachusetts. It would expand required benefits and limit cost-sharing for covered enrollees, affecting state-administered plans, insurers, health plans, HMOs, behavioral health management firms, and third-party administrators operating under Medicaid-managed care arrangements. The practical effect would be to reduce out-of-pocket barriers for patients who need epinephrine for severe allergic reactions.
Sentiment
The available legislative context suggests generally favorable sentiment toward the bill. The Financial Services Committee reported the bill ought to pass, and there are no recorded votes or hearing transcripts indicating opposition in the provided materials. The bill’s framing as a coverage and access measure for a widely used emergency medication suggests it is likely to be viewed as a consumer- and patient-protection proposal.
Contention
No specific points of contention appear in the provided committee record, but the bill’s main policy issue is the scope of the mandate and its cost implications for insurers and public programs. Potential concerns could include added premium or plan costs, administrative implementation across multiple insurance categories, and whether the required coverage should extend to both auto-injectors and pre-filled syringes. Supporters would likely emphasize improved access, affordability, and dosage flexibility for people with severe allergies, while any skeptics would focus on coverage mandates and utilization costs.
In epinephrine auto-injector entities, further providing for definitions and for epinephrine auto-injectors for authorized entities; and making an editorial change.
In epinephrine auto-injector entities, further providing for definitions and for epinephrine auto-injectors for authorized entities; and making an editorial change.
In epinephrine auto-injector entities, further providing for scope of chapter, for definitions and for epinephrine auto-injectors for authorized entities; and making an editorial change.
In school health services, further providing for definitions, for possession and use of asthma inhalers and epinephrine auto-injectors, for school access to emergency epinephrine and for administration of epinephrine auto-injectors by school bus drivers and school crossing guards.
In school health services, further providing for definitions, for possession and use of asthma inhalers and epinephrine auto-injectors, for school access to emergency epinephrine and for administration of epinephrine auto-injectors by school bus drivers and school crossing guards.